缺血性心臟病藥物市場報告（按疾病類別、藥物類別和地區）2025-2033

2024 年全球缺血性心臟病 (IHD) 藥物市場規模達 66 億美元。展望未來， IMARC Group預計到 2033 年市場規模將達到 93 億美元，2025-2033 年期間的成長率 (CAGR) 為 3.73%。

缺血性心臟病 (IHD)，又稱冠心病，是一種透過中斷氧氣和血液供應來損害心肌的疾病。它涉及血管分子變化或動脈粥狀硬化導致冠狀動脈突然閉塞和變窄。這種疾病通常以慢性胸痛和劇烈不適為特徵，如果不及時治療，可能會危及生命。根據病情的嚴重程度，治療缺血性心臟病的藥物種類繁多。例如，如果降膽固醇藥物可以降低血液中的膽固醇水平，那麼醫生會開立阿斯匹靈來降低血液凝固傾向，並使用BETA受體阻斷劑來降低心率和血壓。治療缺血性心臟病的藥物還包括鈣通道阻斷劑和雷諾嗪，它們可以提高BETA受體阻斷劑的療效，並防止冠狀動脈疾病進一步發展。

大眾對介入性醫療程序日益成長的興趣，以及抗心絞痛藥物在治療缺血性心臟病 (IHD) 中的廣泛使用，是推動市場成長的關鍵因素之一。 IHD 藥物正被納入血管成形術、動脈粥狀硬化斑塊切除術和球囊血管成形術等心臟病治療程序中，以確保患者健康康復並預防未來復發。此外，消費者對定期服用這些藥物益處的認知不斷提高，也對其需求產生了顯著影響。過度飲酒、吸煙以及缺乏運動等生活習慣也導致心血管疾病的盛行率不斷上升。此外，全球老年人口的不斷成長，他們極易患心臟病，這也推動了對 IHD 藥物的需求。

本報告回答的關鍵問題：

• 全球缺血性心臟病 (IHD) 藥物市場迄今為止表現如何，未來幾年將如何表現？
• COVID-19 對全球缺血性心臟病 (IHD) 藥物市場有何影響？
• 根據疾病類別，市場是如何分類的？
• 根據藥品類別，市場是如何分類的？
• 全球缺血性心臟病 (IHD) 藥物產業的主要區域市場有哪些？
• 全球缺血性心臟病 (IHD) 藥物產業價值鏈的各個階段有哪些？
• 全球缺血性心臟病 (IHD) 藥物產業的主要促進因素和挑戰是什麼？
• 全球缺血性心臟病 (IHD) 藥物產業的結構是怎麼樣的？主要參與者是誰？
• 全球缺血性心臟病（IHD）藥物產業的競爭程度如何？

目錄

第1章：前言

第2章：範圍與方法

• 研究目標
• 利害關係人
• 資料來源
  • 主要來源
  • 次要來源
• 市場評估
  • 自下而上的方法
  • 自上而下的方法
• 預測方法

第3章：執行摘要

第4章：簡介

• 概述
• 主要行業趨勢

第5章：全球缺血性心臟病（IHD）藥物市場

• 市場概覽
• 市場表現
• COVID-19的影響
• 市場預測

第6章：市場細分：依疾病類別

• 心絞痛
• 心肌梗塞

第7章：市場區隔：依藥品類別

• 抗血脂異常藥物
• 鈣通道阻斷劑
• BETA受體阻斷劑
• 血管緊張素轉換酶抑制劑
• 血管張力素受體阻斷劑
• 血管擴張劑
• 抗血栓藥物

第8章：市場區隔：依地區

• 北美洲
• 歐洲
• 亞太地區
• 中東和非洲
• 拉丁美洲

第9章：SWOT分析

• 概述
• 優勢
• 弱點
• 機會
• 威脅

第 10 章：價值鏈分析

第 11 章：波特五力分析

• 概述
• 買家的議價能力
• 供應商的議價能力
• 競爭程度
• 新進入者的威脅
• 替代品的威脅

第 12 章：價格分析

第 13 章：競爭格局

• 市場結構
• 關鍵參與者
• 關鍵參與者簡介
  • Bayer AG
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Actelion Pharmaceuticals Ltd.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Merck & Co.
  • Eisai Co., Ltd.

The global ischemic heart disease (IHD) drugs market size reached USD 6.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.3 Billion by 2033, exhibiting a growth rate (CAGR) of 3.73% during 2025-2033.

Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.

The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs.

Key Market Segmentation:

Breakup by Disease Class:

• Angina Pectoris
• Myocardial Infarction

Breakup by Drug Class:

• Anti-Dyslipidemic Drugs
• Calcium Channel Blockers
• Beta-Blockers
• ACE Inhibitors
• ARBs
• Vasodilators
• Antithrombotic Agents

Breakup by Region:

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.

Key Questions Answered in This Report:

• How has the global ischemic heart disease (IHD) drugs market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global ischemic heart disease (IHD) drugs market?
• What is the breakup of the market based on the disease class?
• What is the breakup of the market based on the drug class?
• What are the key regional markets in the global ischemic heart disease (IHD) drugs industry?
• What are the various stages in the value chain of the global ischemic heart disease (IHD) drugs industry?
• What are the key driving factors and challenges in the global ischemic heart disease (IHD) drugs industry?
• What is the structure of the global ischemic heart disease (IHD) drugs industry and who are the key players?
• What is the degree of competition in the global ischemic heart disease (IHD) drugs industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Ischemic Heart Disease (IHD) Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Disease Class

• 6.1 Angina Pectoris
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Myocardial Infarction
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

• 7.1 Anti-Dyslipidemic Drugs
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Calcium Channel Blockers
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Beta-Blockers
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 ACE Inhibitors
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 ARBs
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Vasodilators
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Antithrombotic Agents
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Europe
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Middle East and Africa
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Latin America
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Bayer AG
  • 13.3.2 Eli Lilly and Company
  • 13.3.3 Novartis International AG
  • 13.3.4 Pfizer, Inc.
  • 13.3.5 Sanofi S.A.
  • 13.3.6 Actelion Pharmaceuticals Ltd.
  • 13.3.7 Baxter International Inc.
  • 13.3.8 Boehringer Ingelheim International GmbH
  • 13.3.9 Bristol-Myers Squibb Company
  • 13.3.10 Amgen Inc.
  • 13.3.11 F. Hoffmann-La Roche AG
  • 13.3.12 GlaxoSmithKline Plc
  • 13.3.13 Merck & Co.
  • 13.3.14 Eisai Co., Ltd.

List of Figures

• Figure 1: Global: Ischemic Heart Disease Drugs Market: Major Drivers and Challenges
• Figure 2: Global: Ischemic Heart Disease Drugs Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Ischemic Heart Disease Drugs Market: Breakup by Disease Class (in %), 2024
• Figure 4: Global: Ischemic Heart Disease Drugs Market: Breakup by Drug Class (in %), 2024
• Figure 5: Global: Ischemic Heart Disease Drugs Market: Breakup by Region (in %), 2024
• Figure 6: Global: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 7: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 8: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 9: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 10: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 11: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 12: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 13: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 14: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 15: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 16: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 17: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 18: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 19: Global: Ischemic Heart Disease Drugs (ARBs) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 20: Global: Ischemic Heart Disease Drugs (ARBs) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 21: Global: Ischemic Heart Disease Drugs (Vasodilators) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 22: Global: Ischemic Heart Disease Drugs (Vasodilators) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 23: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 24: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 25: North America: Ischemic Heart Disease Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 26: North America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 27: Europe: Ischemic Heart Disease Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 28: Europe: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 29: Asia Pacific: Ischemic Heart Disease Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 30: Asia Pacific: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 31: Middle East and Africa: Ischemic Heart Disease Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 32: Middle East and Africa: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 33: Latin America: Ischemic Heart Disease Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 34: Latin America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 35: Global: Ischemic Heart Disease Drugs Industry: SWOT Analysis
• Figure 36: Global: Ischemic Heart Disease Drugs Industry: Value Chain Analysis
• Figure 37: Global: Ischemic Heart Disease Drugs Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Ischemic Heart Disease Drugs Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Disease Class (in Million USD), 2025-2033
• Table 3: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
• Table 4: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 5: Global: Ischemic Heart Disease Drugs Market: Competitive Structure
• Table 6: Global: Ischemic Heart Disease Drugs Market: Key Players